EP4302754A4 - Composition de nanoparticules d'albumine et de docétaxel stable - Google Patents
Composition de nanoparticules d'albumine et de docétaxel stable Download PDFInfo
- Publication number
- EP4302754A4 EP4302754A4 EP22762626.4A EP22762626A EP4302754A4 EP 4302754 A4 EP4302754 A4 EP 4302754A4 EP 22762626 A EP22762626 A EP 22762626A EP 4302754 A4 EP4302754 A4 EP 4302754A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nanoparticle composition
- albumin nanoparticle
- docetaxel albumin
- stable
- stable docetaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009027 Albumins Human genes 0.000 title 1
- 108010088751 Albumins Proteins 0.000 title 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title 1
- 229960003668 docetaxel Drugs 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110243298 | 2021-03-05 | ||
| PCT/CN2022/079286 WO2022184164A1 (fr) | 2021-03-05 | 2022-03-04 | Composition de nanoparticules d'albumine et de docétaxel stable |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4302754A1 EP4302754A1 (fr) | 2024-01-10 |
| EP4302754A4 true EP4302754A4 (fr) | 2024-12-18 |
Family
ID=83119428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22762626.4A Pending EP4302754A4 (fr) | 2021-03-05 | 2022-03-04 | Composition de nanoparticules d'albumine et de docétaxel stable |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240156774A1 (fr) |
| EP (1) | EP4302754A4 (fr) |
| JP (1) | JP2024510156A (fr) |
| KR (1) | KR20230154864A (fr) |
| CN (2) | CN115025053B (fr) |
| AU (1) | AU2022230634A1 (fr) |
| CA (1) | CA3212544A1 (fr) |
| WO (1) | WO2022184164A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3166973A1 (fr) * | 2020-02-04 | 2021-08-12 | Qun Sun | Formulations de docetaxel |
| CN115957197B (zh) * | 2022-12-22 | 2024-03-01 | 沈阳药科大学 | 包载抗炎药物的西维来司他偶联ros敏感白蛋白纳米粒及其制备方法和应用 |
| WO2024230772A1 (fr) * | 2023-05-09 | 2024-11-14 | 江苏康宁杰瑞生物制药有限公司 | Médicament de polythérapie comprenant un anticorps bispécifique anti-her2 et son utilisation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361731A (zh) * | 2008-08-11 | 2009-02-11 | 张文芳 | 白蛋白稳定的多西紫杉醇冻干制剂及其在治疗肿瘤方面的应用 |
| CN102688200A (zh) * | 2012-05-09 | 2012-09-26 | 刘锋 | 植物类抗癌靶向纳米制剂及其制备方法 |
| CN103202812B (zh) * | 2010-08-09 | 2015-10-28 | 南京大学 | 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法 |
| US20200061020A1 (en) * | 2017-05-01 | 2020-02-27 | Zhuhai Beihai Biotech Co., Ltd. | Formulations and compositions of docetaxel |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006152A1 (fr) * | 1998-07-30 | 2000-02-10 | Novopharm Biotech, Inc. | Composition pharmaceutiquement acceptable comprenant une solution aqueuse de paclitaxel et d'albumine |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| CN1448132A (zh) * | 2002-03-29 | 2003-10-15 | 艾斯·多伯法股份公司 | 改进的基于紫杉醇的抗肿瘤制剂 |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| WO2007027941A2 (fr) * | 2005-08-31 | 2007-03-08 | Abraxis Bioscience, Llc. | Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue |
| LT1931321T (lt) | 2005-08-31 | 2019-05-10 | Abraxis Bioscience, Llc | Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir antimikrobinius agentus |
| CN102988996A (zh) * | 2012-12-19 | 2013-03-27 | 清华大学 | 一种制备稳定的白蛋白纳米颗粒的方法 |
| WO2015018380A2 (fr) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Nanoparticules thérapeutiques et leurs procédés de préparation |
| CN106137969B (zh) | 2015-04-03 | 2020-05-15 | 四川科伦药物研究院有限公司 | 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用 |
| US11154511B2 (en) | 2016-09-29 | 2021-10-26 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Albumin pharmaceutical composition and preparation method therefor |
| CN106333941B (zh) * | 2016-10-24 | 2019-12-13 | 聊城大学 | 一种紫杉醇白蛋白复合物的制备工艺 |
| CN106420665B (zh) * | 2016-10-28 | 2019-04-16 | 浙江省林业科学研究院 | 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法 |
-
2022
- 2022-03-04 EP EP22762626.4A patent/EP4302754A4/fr active Pending
- 2022-03-04 CA CA3212544A patent/CA3212544A1/fr active Pending
- 2022-03-04 JP JP2023554013A patent/JP2024510156A/ja active Pending
- 2022-03-04 AU AU2022230634A patent/AU2022230634A1/en active Pending
- 2022-03-04 CN CN202210209776.9A patent/CN115025053B/zh active Active
- 2022-03-04 CN CN202411190152.2A patent/CN118903027A/zh active Pending
- 2022-03-04 US US18/549,155 patent/US20240156774A1/en active Pending
- 2022-03-04 KR KR1020237030937A patent/KR20230154864A/ko unknown
- 2022-03-04 WO PCT/CN2022/079286 patent/WO2022184164A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361731A (zh) * | 2008-08-11 | 2009-02-11 | 张文芳 | 白蛋白稳定的多西紫杉醇冻干制剂及其在治疗肿瘤方面的应用 |
| CN103202812B (zh) * | 2010-08-09 | 2015-10-28 | 南京大学 | 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法 |
| CN102688200A (zh) * | 2012-05-09 | 2012-09-26 | 刘锋 | 植物类抗癌靶向纳米制剂及其制备方法 |
| US20200061020A1 (en) * | 2017-05-01 | 2020-02-27 | Zhuhai Beihai Biotech Co., Ltd. | Formulations and compositions of docetaxel |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2022184164A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240156774A1 (en) | 2024-05-16 |
| JP2024510156A (ja) | 2024-03-06 |
| EP4302754A1 (fr) | 2024-01-10 |
| WO2022184164A1 (fr) | 2022-09-09 |
| KR20230154864A (ko) | 2023-11-09 |
| CA3212544A1 (fr) | 2022-09-09 |
| CN115025053B (zh) | 2024-08-30 |
| CN115025053A (zh) | 2022-09-09 |
| CN118903027A (zh) | 2024-11-08 |
| AU2022230634A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4302754A4 (fr) | Composition de nanoparticules d'albumine et de docétaxel stable | |
| EP4125821A4 (fr) | Nouveaux lipides et compositions de nanoparticules associées | |
| EP3877521A4 (fr) | Formulations de nanoparticules lipidiques | |
| WO2013177421A3 (fr) | Compositions de nanoparticules d'albumine à revêtement lipidique ainsi que procédés de fabrication et procédé d'utilisation de celles-ci | |
| MX2019002564A (es) | Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas. | |
| EP3962963A4 (fr) | Procédé de formation de complexes d'inclusion contenant des dérivés de bêta-cyclodextrine hydrophiles et compositions associées | |
| EP3600284A4 (fr) | Compositions vaporisables comprenant du cannabinol | |
| EP4051792A4 (fr) | Compositions de dérivés de cas à pam réduit et à pam supprimé et leurs utilisations en modulation génétique | |
| EP3972584A4 (fr) | Compositions de nanoémulsions comprenant des principes biologiquement actifs | |
| EP3278799A4 (fr) | Composition pharmaceutique de nanoparticules d'albumine et de docétaxel, procédé de préparation de ladite composition et son utilisation | |
| EP4028059A4 (fr) | Compositions médicinales stables de cannabidiol | |
| EP3946316A4 (fr) | Compositions pharmaceutiques de cannabidiol | |
| EP3908263A4 (fr) | Nanoparticules ciblées et leurs utilisations associées à des infections fongiques | |
| AU2021380755A9 (en) | Protein-based nanoparticle vaccine for metapneumovirus | |
| WO2017123886A8 (fr) | Méthionine sulfoxyde réductases pour faciliter le repliement des protéines recombinantes in vivo et/ou la stabilisation in vitro | |
| CA2904166C (fr) | Formulations ayant une oxydation reduite | |
| WO2014064652A3 (fr) | Composition pharmaceutique stable d'interféron pégylé alpha-2b | |
| EP3402510A4 (fr) | Compositions et formulations comprenant le cabazitaxel et de l'albumine sérique humaine | |
| EP4267147A4 (fr) | Compositions de nanoparticules lipidiques zwitterioniques et procédés d'utilisation | |
| EP4159190A4 (fr) | Composition de produit cosmétique | |
| EP4212162A4 (fr) | Composition lipidique | |
| EP4097237A4 (fr) | Plateforme de distribution de composition d'échafaudage de nucléase | |
| EP4342496A4 (fr) | Nanoparticules lipidiques | |
| EP4230210A4 (fr) | Composition pharmaceutique stable | |
| IL307741A (en) | Lipid nanoparticle compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230905 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0009140000 Ipc: A61K0009510000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20241120 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/26 20060101ALI20241114BHEP Ipc: A61K 47/18 20170101ALI20241114BHEP Ipc: A61K 47/02 20060101ALI20241114BHEP Ipc: A61P 35/00 20060101ALI20241114BHEP Ipc: A61K 31/337 20060101ALI20241114BHEP Ipc: A61K 9/10 20060101ALI20241114BHEP Ipc: A61K 9/19 20060101ALI20241114BHEP Ipc: A61K 9/51 20060101AFI20241114BHEP |